OSMR: Oncostatin-M-specific receptor subunit beta
Functions as a shared membrane-bound signal-transducing subunit in two distinct receptor complexes, the type II OSM receptor (heterodimer composed of OSMR and IL6ST) and the IL31 receptor complex (heterodimer composed of OSMR and IL31RA) which respectively bind OSM and IL31.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on OSMR, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Vixarelimab | Phase 2 | Roche | Antibody | InhibitorOncostatin-M-specific receptor subunit beta inhibitor | 0 |
- Amyloidosis, primary localized cutaneous, 10.75
- Familial primary localized cutaneous amyloidosis0.60
- Atopic eczema0.48
- Increased total eosinophil count0.47
- Increased circulating IgE concentration0.47
- Ulcerative colitis0.39
- Inflammatory bowel disease0.38
- Crohn disease0.37
- Food allergy0.36
- Failure to thrive0.33
- Eosinophilic gastroenteritis0.33
- Viral infectious disease0.32
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4630885, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q99650, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets